Keywords
How to Cite
Abstract
Drug-induced myopathy is common in clinical practice. However, the development of severe myositis by agents such as all-trans retinoic acid (ATRA) is not usual, with only a few cases reported in the literature. ATRA is currently the standard therapy for the treatment of acute promyelocytic leukemia and is generally well tolerated, with exceptional development of myositis caused by ATRA, with isolated presentation and without association with Sweet’s syndrome. The clinical manifestations are variable, as well as the analytical behavior of muscle enzymes. It is characteristic the resolution of symptoms by the withdrawal of the drug and the use of high doses of steroids. Its early recognition is essential; since only the prompt withdrawal of the causal agent can lead to resolution. We report a case of myositis induced by ATRA.
References
2- Le Quintrec JS, Le Quintrec JL. Drug-induced myopathies. Baillière’s Clinical Rheum. 1991; 5(1):21-38.
3. Holder K. Myalgias and Myopathies: Drug-In-duced Myalgias and Myopathies. FP Essent. 2016; 440:23-27.
4. Kaplan G, Haettich B. Rheumatological symp-tomms due to retinoids. Baillière’s Clinical Rheum. 1991; 5(1):77-97.
5. Oliveira A, Domingo-Domenech E, Arnan M, Gallardo D, Puig I, González-Barca E. All-trans retinoic acid-induced myositis in a case of acute promyelocytic leukaemia. Int Jnl Lab Hem. 2008; 30:254-255.
6. Yu W, Burns C. All-Trans Retinoic Acid-Indu-ced Focal Myositis, Synovitis, and Mononeu-ritis. JCR-J Clin Rheumatol. 2009; 15(7), 358-360.
7. Mayorga Bajo I, Matilla Fernández B, Guindel Jiménez MC, Martín Sanz A, Ortega Valín L, del Pozo Ruiz J. Miositis inducida por ácido trans-retinoico. En: 59º Congreso Nacional Sociedad Española de Farmacia Hospitalaria. Valladolid, 30 de septiembre al 3 de octubre de 2014. España: 2014. p. 1-8.
8. Farah S, Farah S. Isotretinoin-induced acute severe myopathy involving pelvic girdle mus-cles: A case report. Indian J Pharmacol. 2016; 48(5):601-603.
9. Chan K, Yuen S, Joshua D. A case of all-trans retinoic acid-induced myositis in the treatment of acute promyelocytic leukaemia. Clin Lab Haematol. 2005; 27(6):399-401.
10. Van Der Vliet H, Roberson A, Hogan M y col. All-trans-retinoic acid-induced myositis: a description of two patients. Am J Hematol. 2000; 63(2):94-8.
11. Kannan K, Khan H, Jain R, Hussein S, Denni-son D. All-trans retinoic acid-induced myosi-tis. Brit J Haematol. 2005; 131:560.
12. Fabbiano F, Magrin S, Cangialosi C, Felice R, Mirto S Pitrolo F. All-trans retinoic acid indu-ced cardiac and skeletal myositis in induction therapy of acute promyelocytic leukaemia. Brit J Haematol. 2005; 129: 445-445.
13. Plasencia Ternblóm A, Espinosa Martínez E, Hernández Padrón C y col. Complicaciones del tratamiento con ácido transretinoico en la leucemia promielocítica. Rev Cubana Hematol Inmunol Hemoter. 2002; 18(2).
14. Sociedad Argentina de Hematología. Guía de diagnóstico y tratamiento edición 2015. Bue-nos Aires: Sociedad Argentina de Hematolo-gía; 2015.
15. Ministerio de Salud. Secretaría de Políticas, Regulación e Institutos A.N.M.A.T. Guía de buenas prácticas de farmacovigilancia: Minis-terio de Salud de la Nación Argentina; 2015.
All material published in the journal HEMATOLOGÍA (electronic and print version) is transferred to the Argentinean Society of Hematology. In accordance with the copyright Act (Act 11 723), a copyright transfer form will be sent to the authors of approved works, which has to be signed by all the authors before its publication. Authors should keep a copy of the original since the journal is not responsible for damages or losses of the material that was submitted. Authors should send an electronic version to the email: revista@sah.org.ar